Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Amarin (AMRN) Mineral Oil Concerns Not an Oil Spill - Cantor Fitzgerald
November 13, 2018 7:45 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35 price target on Amarin Corporation (NASDAQ: AMRN) saying 'Let's Not Treat Mineral Oil Concerns Like An Oil Spill.'
Chen highlighted:
AMRN disclosed new data in its FAQs and in an 8-K which reinforces our view that mineral oil concerns in the placebo arm are overdone. Therefore, we continue to believe that... MoreAmarin Corp. (AMRN) Achieves Topline Primary & Secondary Endpoint Results from REDUCE-IT, Cardiovascular Outcomes Trial for Vascepa (icosapent ethyl)
November 12, 2018 6:11 AM ESTAmarin Corporation plc (NASDAQ: AMRN) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois. REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with... More
